Sepsis is systemic response to infection with bacteria, viruses, fungi, protozoa, or rickettsiae. If not recognized and treated early, the progression from sepsis to severe sepsis, septic shock, and multiple organ dysfunction syndrome (MODS) are seen (1).
gical advances have improved the outcomes of many infections, the mortality of sepsis and septic shock is high. The incidence of sepsis is more than 500,000 cases each year in the United States. The mortality rate is between 30% and 80% (2) . Severe sepsis is a primary cause of death, especially in intensive care units.
The systemic inflammatory response to infection (systemic inflammatory response syndrome-SIRS) is a complex situation (3) . At the beginning of infection, pathogen-associated microbial patterns (PAMPs) are recognized by pattern recognition receptors (PRRs-cellular receptors expressed on extracellular membranes) and NF-kappa B (NF-KB) release. NF-KB is an important intracellular protein and translocated to the nucleus then the gene transcription of proinflammatory (tumor necrosis factor-α [TNF-α], interleukin [IL]-1, interleukin-6 [IL-6] and anti-inflammatory [IL-10] cytokines) (4) . They trigger many physiologic responses such as stimulation of polymorphonuclear neutrophils, stimulation of the kallikrein-kinin system, activation of factor XII and extrinsic pathway, production of tissue factor (TF), and the activation of coagulation cascade and the complement system (5) .
Why do some children show mild clinical symptoms against infectious agents and others die within a few hours?
Genetic epidemiologic studies suggest that variations in host genetic factors influence the outcome of sepsis (3, (6) (7) (8) (9) . Several genetic polymorphisms have been identified in patients with sepsis and septic shock, including the TNF-α and TNF-β genes, the IL-1 family, the IL-6, the IL-10, the CD-14, the angiotensin-converting enzyme, the mannose binding lectin, the heat shock protein, the Toll-like receptor (TLR)-4, the TLR-2, the plasminogen activator inhibitor type 1 (PAI 1), and the factor V 1691 G-A (FVL) mutation. A large number of genes that are considered related to human sepsis are located on chromosome 6 in the major histocompatibility complex (MHC) (3).
In the regulation of blood coagulation by the protein C pathway, protein C and activated protein C (APC) bind to endothelial cell protein C receptor (EPCR) (10) (11) (12) . If the binding of protein C to EPCR does not occur anyway, the PC activation decreases (11, 13) . EPCR gene transcription can be downregulated by inflammatory cytokines such as TNF-α or IL-1 (12) .
Cathepsin G (CTSG) is a serine protease expressed from promyelocytes and released from activated neutrophils. It can cause platelet activation, leading to intravascular thrombosis (14) . Some polymorphisms of the CTSG gene were identified; Asn 125 Ser allele was associated with cardiovascular or cerebrovascular diseases (15) .
In this study, we investigated the relationship between some polymorphisms and the development and outcome of sepsis in pediatric patients.
PATIENTS AND METHODS
We evaluated 53 patients with severe sepsis who met the criteria for sepsis and severe sepsis, as outlined by Bone and associates (16) . There were 27 girls and 26 boys in this group, with ages ranging from 0 to 15 years. Patients with chronic liver disease, chronic renal failure, chronic pulmonary failure, congenital heart disease, metabolic disease, immune deficiency, injury, or cancer were not included in the study. Samples were obtained from healthy volunteers as control samples. A written consent was obtained from each individual's parents.
DNA Purification
Whole blood samples were placed in tubes with ethylenediamine tetraacetic acid. Genomic DNA was isolated from peripheral blood cells by use of the phenol/chloroform method and analyzed for the polymorphisms of the TNF-α-308 G→A, the IL-6-174 G→C, the PAI-1, the FVL, the EPCR, and the cathepsin G (Ars 125 Ser) polymorphisms as described previously.
TNF-α-308 GA Polymorphism Analysis
TNF-α (nt-308) genotyping was performed by gene amplification and BspHI digestion accord-ing to previously described method (17, 18) . A 194-bp product was amplified using the primers 5'-AATGGAAATAGGTTTTGAGGGT*CAT-3'; and 5'-TCTCGGTTTCTTCTCCATC GC-3' in which T* was not present in the genomic sequence and was introduced to create a potential BspHI site. Cycling was performed at 94°C for 5 minutes followed by 35 cycles of 55°C for 20 seconds, 72°C for 20 seconds, and 94°C for 20 seconds by a final extension step for 7 minutes at 72°C (Temp Cycler, England). PCR product was electrophoresed in a 1% agarose gel. PCR product was digested overnight at 37°C with BspHI (Biolabs, USA) and electrophoresed in a 2.5% agarose gel. BspHI digestion results in two fragments of 169 and 25 bp if an A is present at nt-308.
IL-6-174 GC Polymorphism Analysis
PCR was performed with primers 5'-CAGAA-GAACTCAGATGACTG-3' and 5'-GTGGGGCT-GATTGGAAACC-3' in a total volume of 50 µL containing 5 µL of DNA template, 1U Taq polymerase (Fermentas, Lithuania) in appropriate 10X buffer, 200 µmoL of dNTP each, 1.5 mM MgCl 2 , and 25 pmol of each of the primers. The reaction was run in a Thermalcycler (Biometra, Germany) with an initial denaturation for 5 minutes at 95ºC; two initial cycles of 95ºC denaturation for 30 seconds, 60ºC annealing for 1 minute, 72ºC elongation for 1 minute, followed by two cycles of 57ºC and 25 cycles of 54ºC annealing temperature. At last a final extension at 72ºC for 5 minutes was performed. The products were run in a 2% (wt/vol) agarose gel electrophoresis and bands were visualized under ultraviolet light (UV) after ethidium-bromide staining.
To determine the C allele at position-174, the PCR product was digested by Hsp92II (Promega, USA) for one night at 37ºC. The presence of the C allele creates a restriction site for this enzyme and cuts the PCR product into four fragments of 229 bp, 122 bp, 51 bp, and 29 bp. In G allele carriers 229 bp, 173 bp, and 29 bp fragments are seen. The bands were separated by 2% (wt/vol) agarose gel electrophoresis and visualized under UV after ethidium-bromide staining (19) .
PAI-1 Polymorphism Analysis
Polymerase chain reaction of the PAI-1 4G/5G polymorphism was performed according to previously described method by using primers 5'CACAGAGAGAGTCTGGCCACGT-3' and 5'-CCAACAGAGGACTCTTGGTCT-3'. Amplification was performed for 35 cycles with annealing temperature of 60°C (Ericomp, USA). Amplified 98/99-bp product was digested with Bse LI (Fermentas, Vilnius, Lithuania) at 55°C and subjected to 6% polyacrylamide gel electrophoresis (20) .
FVL Mutation Analysis
Polymerase chain reaction of exon 10 of the factor V gene was performed according to a previously described method.
EPCR Polymorphism Analysis
Polymerase chain reaction of the exon III of the EPCR gene was performed according to previously described method using primers 5'-ACAC-CTGGCACCCTCTCT-3' and 5' -CATCCTTCAGGT CCATCC-3' (2). Amplification was performed for 35 cycles with an annealing temperature of 55ºC (Ericomp, USA). Amplified DNA was subjected to 10% vertical polyacrylamide gel electrophoresis (24) .
CTSG Polymorphism Analysis
DNA was obtained from blood by phenol-chloroform method.genotyping was performed using a polymerase chain reaction (PCR)-restriction fragment length polymorfism technique as previously described. A 263-bp product of Cathepsin G N125S polymorfism was amplified using the primers 5'-GCTGAGCGGGAACGCCTACA-3'; and 5'-CCGGTCCCCCACACAAATCT-3'. Each of the 35 amplification cycles consisted of 1 minute at 94°C, 1 minute at 61°C, and 1 minute at 72°C. The final elongation step was 7 minutes at 72°C. PCR product was electrophoresed in a 2% agarose gel. PCR product was digested overnight at 37°C with SduI and electrophoresed in a 7% PAGE. SduI digestion results in three fragments of 143 bp, 89 bp, and 31 bp if a G is present (25) .
Statistical Analysis
Data were analyzed by use of the Fisher's exact test and a p value less than 0.05 was considered significant. The odds ratio and the 95% confidence interval (CI) were calculated.
RESULTS
Fifty-three patients enrolled in the study and they were divided into two groups: survivors (19 patients) and nonsurvivors (34 patients).
The TNF-α 308 G/A polymorphism frequencies of the patients and controls were 20.8% and 9%, respectively (Table 1) . Patients with this polymorphism had a 2.42-fold risk of severe sepsis and septic shock (95% confidential interval, 0.91-6.49), but we could not find any difference between survivor and nonsurvivor groups ( Table 2) .
The IL-6-174 G/C polymorphism was studied in 44 patients. Genotype distribution and allele frequencies did not differ significantly between, patients and healthy controls (p>0.05) ( Table  3 ). The odds ratio estimating the risk of lethal outcome of severe sepsis was 1.35 (95% confidential interval, 0.43-4) ( Table 4 ). The distribution percentage of PAI-1 promoter genotypes 4G/4G, 4G/5G, and 5G/5G in the patients and in the controls were 54.8%, 33.3% and 11.9%; 24.8%, 50.4%, and 24.8%, respectively ( Table 5 ). Patients carrying the PAI-1 4G/4G genotype were at an increased risk of severe sepsis and septic shock (risk ratio 2.2; 95% confidential interval, 1.1-4.2). There was no difference between survivor and nonsurvivor groups (p>0.05) ( Table 6 ).
When we analyzed factor V 1691 G/A polymorphism, we did not find any association with this mutation on susceptibility of severe sepsis and the risk of death as seen in literature (p>0.05, OR= 1.24 95% confidential interval 0.39-3.9) ( Tables 7, 8 ).
The distribution of the 23 bp insertion of the exon III of the EPCR gene was studied in 45 patients. Three (6.7%) of them carried this mutation. In the control group the percentage of carrying this mutation was 1.25%. Genotype distribution and allele frequencies did not differ significantly between patients with severe sepsis and healthy controls (p>0.05) ( Table 9 ). However the odds ratio for this EPCR mutation was significantly increased in patients (OR: 5.33; 95% confidence interval 0.86-32.9). There was no difference between survivor and nonsurvivor groups ( Table 10 ). The Cathepsin G Asn 125 Ser allele frequency was found 0.04 in patients and controls. There was no statistically difference between them ( Table 11 ). The odds ratio for patients was 1.1 (95% CI 0.26-4.7) and for mortality was 0.82 (95% CI 0.08-7.94) ( Table 12) .
DISCUSSION
Genetic epidemiologic studies suggest a strong genetic influence on the progression and mortality from sepsis (3,6-9). Sorensen and colleagues reported their research that if a biologic parent died of infection before the age of 50 years, the child had a 5.81 relative risk of dying of infec-tion (95% CI, 2.47-13.7) (26). They conclude that genetic influences are responsible for the major part of the familial influence on overall mortality.
Most positive association studies examine genes for important inflammatory molecules such as IL-1 family, IL-6, IL-10, IL-18, TNF-α, in the complement pathway the mannose binding lectin, properdin, factor D, C3, late complement deficiency (LCCD); in coagulation and fibrinolytic system such as tissue-plasminogen activator, PAI-1, FVL, protein C and thrombomodulin; molecules for recognition of antigens such as toll-like receptors and CD-14 (27) (28) (29) (30) (31) (32) .
In this study, we investigated whether variants of TNF-α, IL-6, PAI-1, FV 1691 G/A, EPCR, or CTSG genes might influence the risk and mortality of severe sepsis in children. It was found that the TNF-α 308 G/A polymorphism was higher than the control group. Patients with this allele had a 2.42-fold risk of severe sepsis. Holmes and associates (3) reported summary of some articles and said there was evidence that the TNF-α-308 A allele is associated with adverse outcome in many inflammatory diseases and sepsis. Some studies indicate that TNF-α-308 A allele is strongly associated with susceptibility to septic shock and death due to septic shock (33) (34) (35) . We found that IL-6 promoter polymorphism (-174 G/C) did not influence the incidence and mortality of sepsis. Sclüter and colleagues studied this polymorphism and they did not find any association with sepsis (36). Ahrens and associates reported that the homozygous IL-6-174 G polymorphism was predictive for the development of sepsis (37) . FVL mutation did not affect the outcome of sepsis in our patient as seen in the literature (32) .
The CTSG gene polymorphism, another candidate gene for sepsis and septic shock, located on chromosome 14q 11.2, also did not influence the risk and course of severe sepsis (14, 15) .
Hermans and colleagues reported that the patient with the 4G homozygous genotype had higher PAI-1 concentrations and had an increased risk of death (38) . In another study it was reported that the relative risk of death was 2.9 for the 4G/4G patients (39) . In this study, we found that patients with the PAI-1 4G/4G allele had an increased risk of severe sepsis (OR:2.2; 95% CI, 1.1-4.2) ( Table 5 ), but we did not find any effect on mortality ( Table 6) .
The protein C anticoagulant pathway serves as a major system for controlling thrombosis and limiting inflammatory responses. EPCR binds protein C and APC on the cell surface. EPCR does not have any direct anticoagulant effect but it influences the rate of PC activation by the thrombin/thrombomodulin complex (12) . Another function of the EPCR appears to be in regulating the host response to septic shock (11) .
In animal models if the binding of protein C to EPCR was blocked, infusion of a sublethal dose of Escherichia coli caused death. In the literature there are some reports about EPCR polymorphisms in patients with thrombosis (13, 40) . However, we could not find any report in English about the effect of EPCR gene alterations on the pathogenesis of severe sepsis and septic shock. We found the odds ratio for this mutation was significantly increased in patients with severe sepsis (OR: 5.33; 95% CI 0.86-32.9). But we could not find any difference between survivor and nonsurvivors (Tables 9, 10).
In conclusion, our findings suggest that the analyzed genetic variants of TNF-α 308 G/A, PAI-1 4G/4G, and EPCR influence the risk of severe sepsis in children. Although the small number of patients with severe sepsis prevents us from drawing a conclusion about the significance of the coexistence of these polymorphisms, our findings are interesting. In addition, there are very limited studies in childhood. Further investigation should be done with a larger patient group to determine the importance of these genetic polymorphisms in the development and complications of severe sepsis.
